OLYMPUS LABS LAUNCHES PRE-ICO BRINGING A NEW FINANCIAL ECOSYSTEM TO THE BLOCKCHAIN WORLD
New York, NY, Nov. 29, 2017 (GLOBE NEWSWIRE) -- As blockchain and cryptocurrency companies continue to raise millions of dollars in funding, there's an urgent need in the market for companies and investors to be able to better manage its cryptocurrency assets with hedging products and tools. Olympus Labs believes that by offering financial tools and protocol, crypto- based companies and investors will be able to have more control by protecting their downside risk in an otherwise extremely volatile market.
"Olympus Labs is an integrator of cryptocurrency-based financial products (e.g., indices, ETFs, options, futures, etc.). Olympus, third-party financial product developers, and Fintech applications build the products which include but are not limited to exchanges, market analytics tools, payment services, etc. (e.g., Kyber, Shapeshift, Sentiment)," explains Kai Chen, CEO of Olympus Labs.
On November 27, 2017 due to the high demand from outside investors Olympus Labs opened its doors for its Pre-ICO token sale.
The Olympus product is viable and has huge long-term potential. As for competition, it fills an evidently empty space in the cryptocurrency market, practically guaranteeing that Olympus' offerings will be used-and that this usage will generate profits. Olympus's mission is to "define the protocol for crypto-based derivatives," and it seems clear that these products will help mature the market beyond the current spot market.
The first of Olympus's products will allow one to borrow and lend bitcoin. Cryptocurrency index funds will be the second Olympus product to hit the market. These index funds will allow investors to buy into multiple cryptocurrencies at once, with profits moving with the market as a whole instead of with individual spot cryptocurrencies. Through customizable fintech-focused smart contracts, exchanges will be able to quickly and easily make their own indices which track the overall trend of cryptocurrencies traded on that exchange.
To Participate in the Pre-ICO
The Olympus Labs Token Sale started at 8 pm (GMT+8/UTC 12pm), 27 November 2017, and ends at 8pm (GMT+8/UTC 12 pm), 3 December 2017.Olympus Presale terms: Investors contributing more than 100 ETH, will get 10% bonus (1 ETH = 677 Olympus tokens). This will take place after ICO, and those who passed the KYC process, will be issued MOT, the rest who failed in KYC, will be refunded with ETH. For additional information and terms of the sale please visit the Olympus Labs website.
During the registration period (27 November 2017 to 3 December 2017), please visithttps://kyc.olympuslabs.io/.
About OLYMPUS LABS
Olympus is led by a cohesive team with extensive expertise in both the traditional financial markets and blockchain technology. Olympus Founder and CEO Kai Chen started his career on Wall Street with Morgan Stanley, and he later went on to work for McKinsey and PIMCO. Our development team includes Google's former development community lead for China. On the business side, we have Danielle Sabrina, a highly sought-after marketing expert and veteran of several successful ICOs, and has helped her clients achieve prestigious awards such as Inc 500, Forbes Next Billion Dollar Startup, Entrepreneur 360 among other top level recognition. Danielle's work has also been featured in Huffington Post and Entrepreneur. Olympus also has a strong advising board made up of former executives at Morgan Stanley and McKinsey.
OLYMPUS LABS Social Media
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a88937da-05db-437e-92f0-07cc02b4dd8f
What Vibes Your Tribe
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OLYMPUS LABS via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation19.3.2018 13:09 | Pressemelding
Real-Time Information Matched with GPS Locations Provides Accurate Delivery Information WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, introduces Elemica Trace, a solution that provides real-time shipment and risk visibility to customer service, transport planners, and supply chain managers, allowing them to monitor and proactively manage the movement of products to customers and inbound to manufacturing centers. "Shipment disruptions occur and teams can spend hours manually tracking down what is happening. What's worse, sometimes your customer complaint is the first indication you have of a late shipment," said Rich Katz, CTO of Elemica. "Trace eliminates the time and stress of tracking shipments and enables your teams to increase the positive interactions with your customers." Elemica Trace uses shipment data, carrier signals, a geo-location interface, and predictive algorithms to identify shipments in
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial19.3.2018 12:00 | Pressemelding
The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018 CALGARY, Alberta, March 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial. The trial's first patient was enrolled on November 11th, 2015. The goal of the trial is to confirm the effect of Resverlogix' lead drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL). The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke. Secondary pre-specified endpoints in the trial will also examine renal function and MACE in patien
SolarWinds Places Highest on the Ability to Execute Axis in 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics19.3.2018 11:30 | Pressemelding
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, placed highest on the ability to execute axis in the 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics1. This Gartner report evaluated 22 suppliers of Network Performance Monitoring and Diagnostics products. The firm's evaluation criteria for ability to execute included the following: product or service, overall viability, sales execution and pricing, market responsiveness and record, marketing execution, customer experience, and operations. Of all the vendors evaluated in the report, SolarWinds placed highest on the ability to execute axis. "For three years in a row, Gartner has positioned us as highest on the ability to execute axis in the Magic Quadrant for Network Performance Monitoring and Diagnostics. In our view, this result confirms our commitment to helping our customers manage their network operations with a powerful
Record High Number of Toll Transactions Cleared in Ireland in 201719.3.2018 10:51 | Pressemelding
ISSY LES MOULINEAUX, France, March 19, 2018 (GLOBE NEWSWIRE) -- The number of transactions processed through emovis's toll interoperability cloud-based hub in Ireland has reached a record high with over 50 million transactions cleared in 2017. Thanks to its toll interoperability solution, emovis is contributing to the improved mobility of millions of Irish drivers, by allowing them to travel seamlessly with just one toll tag across the whole country. As of January 2018, over 650,000 toll transponders are in use. With this new success, emovis demonstrates its leadership in designing and operating innovative mobility solutions that offer the best levels of service for road users in Ireland and throughout the world. About eToll.ie emovis was awarded the contract for managing Ireland's toll interoperability hub by the National Roads Authority (now Transport Infrastructure Ireland) in June 2013 following a competitive tender. As part of this contract, emovis designed, developed and is curre
Phenom People Set to Attend UNLEASH London19.3.2018 09:00 | Pressemelding
Candidate Experience Software Pioneer Attends UK Conference HORSHAM, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Phenom People, the leader in Talent Relationship Marketing (TRM), announced today that it will attend UNLEASH Conference & Expo on March 20-21 at the ExCel London. "We are no stranger to UNLEASH's strong turnout of highly passionate and forward-thinking individuals who are ready for the next big thing in technology. The inspiration and exchange of new ideas from the world's greatest thought leaders UNLEASH draws in every year, is what we look forward to the most," said Mahe Bayireddi CEO at Phenom People. "Our presence at this year's UNLEASH is vitally important as we continue to emerge as a global TRM leader with a growing list of European clients." UNLEASH, formerly HR Tech World, is held around the globe and was created to enhance the Future of Work by marrying technology with efficient business practices. UNLEASH London's speaker line-up consists of many big-league names inc
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights16.3.2018 22:32 | Pressemelding
Investor Conference Call on Tuesday, March 27th at 10:00 am ET NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the fourth quarter. The Company will host a call to update investors on recent clinical developments and year-end financial results on Tuesday, March 27th at 10:00 am (Eastern). Interested parties are invited to participate in the call by dialing 877-407-9210 (toll free domestic) or 201-689-8049 (International). "The past year was marked by several defining events in the company's history, having advanced our two lead clinical programs, EB-101 in Epidermolysis Bullosa and ABO-102 in MPS IIIA, and initiated our third clinical program, ABO-101 in MPS IIIB. The strong safety and biopotency data observed in our three active clinical trials and the s
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom